Back to discover
Drug

Pentylenetetrazole

In clinical development
Emerging researchEarly-to-mid development

Also known as Pentetrazol, pentaetrazol, PENTYLENETETRAZOL.

RxNorm8015ChEMBLCHEMBL116943ATCR07AB03ATCR07AB53UNIIWM5Z385K7T
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Pentylenetetrazole
Aliases & brands
PentetrazolpentaetrazolPENTYLENETETRAZOL
RxNorm CUI
8015
ChEMBL ID
CHEMBL116943
ATC codes
R07AB03R07AB53
UNII
WM5Z385K7T

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
1
Discontinued
PHASE DISTRIBUTIONn = 1
Phase 21

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes2
Epilepsy1Kindling, Neurologic1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences1
Leading researchers
  • Aguilar F1
  • Bonansco C1
  • Chacana-Véliz L1
  • Chávez AE1
  • Díaz F1
  • Fuenzalida M1
  • González-Arancibia C1
  • Martorell A1
Leading institutions
free-text, unnormalised
  • Center for Advanced Microscopy CMA BIOBIO1
  • Instituto de Fisiología1
  • Instituto de Neurociencia1
  • Laboratory of Neurobiology and Stem Cells1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials